Okay, let's tackle this question about the preferred anesthetic in renal failure. First, I need to remember which anesthetics are safe for patients with renal issues. Renal failure affects drug metabolism and excretion, so the anesthetic should ideally be eliminated through non-renal pathways.

The core concept here is understanding the pharmacokinetics of local anesthetics. Local anesthetics like lidocaine are metabolized in the liver, which is important for patients with renal impairment. Bupivacaine, on the other hand, is primarily metabolized by the liver but has active metabolites that might accumulate in renal failure. So maybe lidocaine is better? Wait, but there's also prilocaine and mepivacaine. Oh, right, prilocaine is metabolized to orthotoluidine, which is excreted renally. So in renal failure, prilocaine might not be the best choice.

The correct answer is likely lidocaine. Let me check the options again. If the options include lidocaine, that's the one. The question says "Preferred anaesthetic in renal failure," so the answer should be a local anesthetic with minimal renal excretion. Lidocaine is metabolized by the liver into metabolites that are inactive, so even if the kidneys aren't working, it's safer.

Now, the wrong options: Let's say option A is bupivacaine. It's not ideal because its metabolites, like pipecoloxylidide, can accumulate in renal failure, causing toxicity. Option B might be prilocaine, which as mentioned, has orthotoluidine that's excreted by the kidneys. Option C could be mepivacaine, which is also metabolized by the liver but has some renal excretion of metabolites. So the best choice is lidocaine.

Clinical pearl: Remember that lidocaine is the preferred local anesthetic in renal failure due to hepatic metabolism. Avoid prilocaine and bupivacaine in such patients.

**Core Concept**
The pharmacokinetics of local anesthetics determine their safety in renal failure. Anesthetics metabolized hepatically with minimal renal excretion are preferred to avoid drug accumulation and toxicity in patients with impaired renal function.

**Why the Correct Answer is Right**
Lidocaine is metabolized in the liver via hepatic CYP450 enzymes into inactive metabolites (e.g., monoethylglycinexylidide), which are excreted in urine. In renal failure, the inactive metabolites do not accumulate significantly, making lidocaine safer compared to agents with active metabolites or renal excretion pathways. This hepatic clearance pathway minimizes toxicity risk in patients with compromised kidney function.

**Why Each Wrong Option is Incorrect**
**Option A: Bupivacaine** – Its active metabolite, pipecoloxylidide, is excreted renally. Accumulation in renal failure can cause CNS and cardiac toxicity.
**Option B: Prilocaine** – Metabolized to orthotoluidine, which is renally excreted. Accumulation in renal failure may lead to methemoglobinemia.
**Option C: Mepivacaine** – Primarily metabolized hepatically but has some renal excretion of active metabolites, increasing toxicity

✓ Correct Answer: B. Atracurium